<?xml version='1.0' encoding='utf-8'?>
<document id="31615114"><sentence text="Metabolism, Transport and Drug-Drug Interactions of Silymarin."><entity charOffset="52-61" id="DDI-PubMed.31615114.s1.e0" text="Silymarin" /></sentence><sentence text="Silymarin, the extract of milk thistle, and its major active flavonolignan silybin, are common products widely used in the phytotherapy of liver diseases"><entity charOffset="0-9" id="DDI-PubMed.31615114.s2.e0" text="Silymarin" /><entity charOffset="61-82" id="DDI-PubMed.31615114.s2.e1" text="flavonolignan silybin" /><pair ddi="false" e1="DDI-PubMed.31615114.s2.e0" e2="DDI-PubMed.31615114.s2.e0" /><pair ddi="false" e1="DDI-PubMed.31615114.s2.e0" e2="DDI-PubMed.31615114.s2.e1" /></sentence><sentence text=" They also have promising effects in protecting the pancreas, kidney, myocardium, and the central nervous system" /><sentence text=" However, inconsistent results are noted in the different clinical studies due to the low bioavailability of silymarin"><entity charOffset="109-118" id="DDI-PubMed.31615114.s4.e0" text="silymarin" /></sentence><sentence text=" Extensive studies were conducted to explore the metabolism and transport of silymarin/silybin as well as the impact of its consumption on the pharmacokinetics of other clinical drugs"><entity charOffset="77-86" id="DDI-PubMed.31615114.s5.e0" text="silymarin" /><entity charOffset="87-94" id="DDI-PubMed.31615114.s5.e1" text="silybin" /><pair ddi="false" e1="DDI-PubMed.31615114.s5.e0" e2="DDI-PubMed.31615114.s5.e0" /><pair ddi="false" e1="DDI-PubMed.31615114.s5.e0" e2="DDI-PubMed.31615114.s5.e1" /></sentence><sentence text=" Here, we aimed to summarize and highlight the current knowledge of the metabolism and transport of silymarin"><entity charOffset="100-109" id="DDI-PubMed.31615114.s6.e0" text="silymarin" /></sentence><sentence text=" It was concluded that the major efflux transporters of silybin are multidrug resistance-associated protein (MRP2) and breast cancer resistance protein (BCRP) based on results from the transporter-overexpressing cell lines and MRP2-deficient (TR-) rats"><entity charOffset="56-63" id="DDI-PubMed.31615114.s7.e0" text="silybin" /></sentence><sentence text=" Nevertheless, compounds that inhibit the efflux transporters MRP2 and BCRP can enhance the absorption and activity of silybin"><entity charOffset="119-126" id="DDI-PubMed.31615114.s8.e0" text="silybin" /></sentence><sentence text=" Although silymarin does inhibit certain drug-metabolizing enzymes and drug transporters, such effects are unlikely to manifest in clinical settings"><entity charOffset="10-19" id="DDI-PubMed.31615114.s9.e0" text="silymarin" /></sentence><sentence text=" Overall, silymarin is a safe and well-tolerated phytomedicine"><entity charOffset="10-19" id="DDI-PubMed.31615114.s10.e0" text="silymarin" /></sentence><sentence text="" /></document>